Summit Speaker Spotlight: Dr. Timothy R. Coté

by | Aug 23, 2016 | 1 comment

Tim1-(1)-fixedDr. Timothy R. Coté is a leading national regulatory expert in orphan drug development. With 23 years of Federal service at the FDA, NIH, and CDC, Dr. Coté recently served as the Director of the FDA Office of Orphan Products Development (OOPD) from Sept 2007 through May 2011.

In this role, he implemented the Orphan Drug Act and personally signed decisions on 1400+ orphan drug designation applications. An anatomic pathologist and medical epidemiologist, he has published 80 peer-reviewed articles on areas as diverse as HIV/AIDS-related malignancies, typhoid fever epidemics, and the impact of bicycle helmet laws on injury statistics.  

Dr. Coté is founder and CEO at Cote Orphan; he directs and trains staff to create compelling regulatory submissions that are finely tuned to each client’s business strategy and to the unwritten rules within the FDA.

Dr. Coté received a bachelor’s degree from Syracuse University, a medical doctorate from the Howard University College of Medicine, and a master’s degree in Public Health from Harvard School of Public Health.

HNF has invited Dr. Coté to lead the discussion on Public Policy. We will cover issues such as better AFO (leg-bracing) options, fast-tracking drug discoveries and clinical trials, applying for disability benefits, Medicare/Medicaid and services. Let’s empower the CMT/IPN community to unite as one voice to implement change in the system.

Learn more on this topic

Related Blog Posts

CMT Kids Video

The Hereditary Neuropathy Foundation is currently seeking 10 second video clips of CMT patients under the age of 16, performing daily activities.

Summit Panelist Spotlight: Mitchell Warner

Bracing is used in the management Charcot-Marie-Tooth to support and hold a part of the body compromised by muscle weakness, muscular atrophy, sensory impairment. Bracing is also used to help correct skeletal deformity.

Summit Panelist Spotlight: Brent Baker

With respect to CMT, Dr. Baker’s team has collaborated with Drs. Michael Sereda and Klaus Nave of the Max Planck Institute for Experimental Medicine (MPI) to utilize their CMT1A transgenic rat and established the initial CMT1A rat colony in the United States.

Join the conversation

Leave a Comment

1 Comment

  1. Linda Westmoreland

    Dr. Cote’,
    I have CMT1A. I also have peripheral neuropathy. I would like to take part in this study. I am 67 years old and I have pain with neuropathy from the minute I get up until the end of day. I take Gabapentin, Methodone, Percocet and Tramadol for pain. My right leg has the most pain, however, I have cramps all over my body. It is so difficult for me to put on my AFO’S and tie my shoes. My body cramps while I am doing this. It would be wonderful if a new drug would help me”


Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news